COVID-19 rapid guideline: managing COVID-19COVID-19 rapid guideline: Managing COVID-19 Main editor NICE Publishing, version history and subscription 26.0 published on 15.06.2022 The National Institute for Health and Care Excellence (NICE) logo The National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline: Managing COVID-19 Contact COVID-19 rapid guideline: Managing COVID respiratory support .............................................................................................................................................................58 7. Therapeutics for COVID-19 ..............................................................................................................................................................................................89 7.1
COVID-19 Vaccine (Spikevax) (previously COVID-19 Vaccine Moderna) Spikevax (previously COVID-19 Vaccine Moderna) | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview programmes * History of EMA * Careers * Procurement * Glossaries * About this website * Data protection and privacy * Contacts 1. Home 2. Medicines 3. Spikevax (previously COVID-19 Vaccine Moderna) Spikevax (previously COVID-19 Vaccine Moderna)RSSAuthorisedThis medicine is authorised for use in the European Union COVID-19 mRNA vaccineMedicineHumanAuthorised Page contents * Overview * Product information
COVID-19 rapid guideline: managing the long-term effects of COVID-19COVID-19 rapid guideline: managing the long-term effects of COVID-19 Main editor National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners (RCGP) Publishing, version history and subscription 1.14 published on 01.03.2022 NICE, RCGP .................................................................................................................................................................................................102 References ...............................................................................................................................................................................................................................104 COVID-19 rapid guideline: managing the long-term effects of COVID-19 - NICE, RCGP, and..
A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Search Journals Library * Journals * Outputs and external publications * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health and Social Care Delivery Research A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses
Managing nurse redeployment during the Covid-19 pandemic, lessons for future redeployment: a qualitative study Managing nurse redeployment during the Covid-19 pandemic, lessons for future redeployment: a qualitative study | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Journals Journals * Outputs and external publications * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health and Social Care Delivery Research Managing nurse redeployment during the Covid-19 pandemic, lessons for future redeployment
Lockdown and licensed premises: COVID- 19 lessons for alcohol policy Lockdown and licensed premises: COVID- 19 lessons for alcohol policy | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Journals Journals * About journals * Efficacy and Mechanism Evaluation * Global Health Research * Health For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Public Health Research Lockdown and licensed premises: COVID- 19 lessons for alcohol policy 1. Journals Library 2. Public Health Research 3. Lockdown and licensed premises: COVID- 19 lessons for alcohol policy * Type: External Article
Effect of a 2- week interruption in methotrexate treatment versus continued treatment on COVID- 19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial Effect of a 2- week interruption in methotrexate treatment versus continued treatment on COVID- 19 booster vaccine immunity in adults with inflammatory conditions (VROOM study * Support for researchers * Policies * FAQs * Contact us Close menu Efficacy and Mechanism Evaluation Effect of a 2- week interruption in methotrexate treatment versus continued treatment on COVID- 19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial 1. Journals Library 2. Efficacy and Mechanism Evaluation 3. Effect of a 2- week
ffect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial Effect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority * Policies * FAQs * Contact us Close menu Efficacy and Mechanism Evaluation Effect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial 1. Journals Library 2. Efficacy and Mechanism Evaluation 3. Effect of a 2- week interruption in methotrexate treatment on COVID- 19
Nurses' experiences and sense making of COVID- 19 redeployment and the impact on well- being, performance, and turnover intentions: a longitudinal multimethod study Nurses' experiences and sense making of COVID- 19 redeployment and the impact on well- being, performance, and turnover intentions: a longitudinal multimethod study | NIHR Journals Library opens in a new window Skip to main content Research Nurses' experiences and sense making of COVID- 19 redeployment and the impact on well- being, performance, and turnover intentions: a longitudinal multimethod study 1. Journals Library 2. Health and Social Care Delivery Research 3. Nurses' experiences and sense making of COVID- 19 redeployment and the impact on well- being, performance, and turnover intentions: a longitudinal multimethod study
The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY) The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY) | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals * Production process * Outputs and external publications * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health and Social Care Delivery Research The impact of redeployment during COVID-19 on nurse well-being, performance
Lessons from the PROTECT-CH COVID-19 platform trial in care homes Lessons from the PROTECT-CH COVID-19 platform trial in care homes | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Journals Journals * About journals * Efficacy and Mechanism Evaluation * Global Health Research * Health For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health Technology Assessment Lessons from the PROTECT-CH COVID-19 platform trial in care homes 1. Journals Library 2. Health Technology Assessment 3. Lessons from the PROTECT-CH COVID-19 platform trial in care homes * Type: Research
CONTACT: a non-randomised feasibility study of bluetooth-enabled wearables for contact tracing in UK care homes during the COVID-19 pandemic CONTACT: a non- randomised feasibility study of bluetooth- enabled wearables for contact tracing in UK care homes during the COVID- 19 pandemic | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu - enabled wearables for contact tracing in UK care homes during the COVID- 19 pandemic 1. Journals Library 2. Health Technology Assessment 3. CONTACT: a non- randomised feasibility study of bluetooth- enabled wearables for contact tracing in UK care homes during the COVID- 19 pandemic * Type: External Article Our publication formats * Authors: Thompson CA, Willis T, Farrin A, Gordon A, Daffu- O'Reilly
'Smart' BLE wearables for digital contact tracing in care homes during the COVID-19 pandemic: a process evaluation of the CONTACT feasibility study 'Smart' BLE wearables for digital contact tracing in care homes during the COVID- 19 pandemic a process evaluation of the CONTACT feasibility study | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals tracing in care homes during the COVID- 19 pandemic a process evaluation of the CONTACT feasibility study 1. Journals Library 2. Health Technology Assessment 3. 'Smart' BLE wearables for digital contact tracing in care homes during the COVID- 19 pandemic a process evaluation of the CONTACT feasibility study * Type: External Article Our publication formats * Authors: Thompson CA, Daffu-O'Reilly A, Willis
Post COVID-19 condition and new onset diseases after COVID-19: A rapid review NIPH's website uses cookies. Read more about our use of cookies in our privacy policy.CloseHopp til innholdSearch for:SøkMenuInfectious diseases & VaccinesMental & Physical healthEnvironment & LifestyleHealth in NorwayQuality & KnowledgeResearch & Access to dataAbout NIPHCloseSYSTEMATIC REVIEWPost COVID-19 condition and new onset diseases after COVID-19: A rapid reviewPublished 19.12.2022We aimed to summarise research on the proportion of patients who get long-term symptoms, which long-term symptoms occur after COVID-19, how long the symptoms persist and which patient groups that have the greatest risk of experiencing long-term symptoms. Les på norsk Share/tip Print Get alerts about changes Downloadable as PDF
Nirmatrelvir, ritonavir (Paxlovid) - To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19 Skip to main contentSkip to FDA SearchSkip to in this section menuSkip to footer links An official website of the United States government Here’s how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search HomePage Not FoundWe can't find
COVID-19 Living Evidence Synthesis 8 - What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern (Version 20) COVID-19 Living Evidence Synthesis # 8 (Version 8.20: 17 Jan 2023) Question What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern? Findings For vaccine to living evidence syntheses on vaccine effectiveness using the following mechanisms: 1) PubMed via COVID-19+ Evidence Alerts; 2) systematic scanning of pre-print servers; 3) updates to the COVID-END inventory of best evidence syntheses; and 4) cross-check with updates from the VESPa team. We included studies and updates to living evidence syntheses identified up to two days before the version release